New treatment for severe respiratory distress syndrome
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier
This study is testing a new medication that could help people with severe breathing problems caused by ARDS by improving how well their bodies deliver oxygen, and it's designed for patients who are struggling with this serious condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Illexcor Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10875488 on NIH RePORTER |
What this research studies
This research investigates a novel pharmacologic approach to treat severe acute respiratory distress syndrome (ARDS), a critical condition characterized by severe breathing difficulties and low oxygen levels. The study aims to develop a potent allosteric hemoglobin modifier that could enhance oxygen delivery to tissues, potentially improving patient outcomes. By focusing on a new therapeutic strategy, the research seeks to address the limitations of current treatments, which often fail to significantly reduce mortality rates in ARDS patients. The methodology involves clinical trials to evaluate the safety and efficacy of this new treatment in affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults diagnosed with severe acute respiratory distress syndrome who are experiencing significant respiratory failure.
Not a fit: Patients with mild respiratory issues or those not diagnosed with ARDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients suffering from severe ARDS.
How similar studies have performed: While there have been advancements in ARDS treatment, this approach is novel and has not been extensively tested in clinical settings.
Where this research is happening
Richmond, United States
- Illexcor Therapeutics, LLC — Richmond, United States (Active)
Researchers
- Principal investigator: Light, David Richard — Illexcor Therapeutics, LLC
- Study coordinator: Light, David Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.